Cwm LLC purchased a new stake in shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,800 shares of the company's stock, valued at approximately $55,000. Cwm LLC owned 0.05% of ALPS Medical Breakthroughs ETF as of its most recent filing with the SEC.
Several other institutional investors have also recently made changes to their positions in SBIO. Captrust Financial Advisors raised its position in shares of ALPS Medical Breakthroughs ETF by 903.6% during the 1st quarter. Captrust Financial Advisors now owns 1,666 shares of the company's stock valued at $56,000 after buying an additional 1,500 shares during the period. International Assets Investment Management LLC purchased a new stake in ALPS Medical Breakthroughs ETF in the fourth quarter valued at approximately $202,000. Jane Street Group LLC purchased a new stake in ALPS Medical Breakthroughs ETF in the first quarter valued at approximately $208,000. Citadel Advisors LLC purchased a new stake in ALPS Medical Breakthroughs ETF in the third quarter valued at approximately $290,000. Finally, Kestra Advisory Services LLC raised its position in ALPS Medical Breakthroughs ETF by 7.9% in the third quarter. Kestra Advisory Services LLC now owns 13,439 shares of the company's stock valued at $405,000 after purchasing an additional 985 shares during the period.
Get ALPS Medical Breakthroughs ETF alerts:ALPS Medical Breakthroughs ETF Price Performance
Shares of NYSEARCA SBIO opened at $29.97 on Monday. ALPS Medical Breakthroughs ETF has a 52-week low of $23.58 and a 52-week high of $35.51. The business's 50 day moving average is $28.61 and its two-hundred day moving average is $29.92.
About ALPS Medical Breakthroughs ETF
(Get Rating)
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Featured Stories
- Get a free copy of the StockNews.com research report on ALPS Medical Breakthroughs ETF (SBIO)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
Want to see what other hedge funds are holding SBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Rating).
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.